3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Breast Neoplasms
3
Colorectal Neoplasms
2
Breast Diseases
2
Thrombocythemia, Essential
1
Polycythemia Vera
1
Lymphedema
1
Liver Neoplasms
1
Hypogonadism
1
Glioma
1
Fatigue Syndrome, Chronic
1
Eunuchism
1
Adenoma
1
Interventions
fludarabine phosphate
21
Cyclophosphamide
20
Peripheral Blood Stem Cell Transplantation
19
Busulfan
16
Tacrolimus
14
Whole-Body Irradiation
12
Methotrexate
12
Mycophenolic Acid
11
Cyclosporine
11
Antilymphocyte Serum
10
fludarabine
6
Filgrastim
6
peginterferon alfa-2a
5
ruxolitinib
4
Radiotherapy
4
Methylprednisolone
4
Melphalan
4
Flow Cytometry
4
Etoposide
4
Decitabine
4
Aspirin
4
Stem Cell Transplantation
3
Injections
3
Cytogenetic Analysis
3
Cytarabine
3
Biopsy
3
Azacitidine
3
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
3
merphos
2
aldesleukin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Thrombocythemia, Essential
×
Drug Evaluation
×
Clear all
NCT02577926
2025-06-10
Ruxo-BEAT
RWTH Aachen University
Phase 2
Active not recruiting
207 enrolled